TY  - JOUR
A1  - Betschel, Stephen
A1  - Badiou, Jacquie
A1  - Binkley, Karen
A1  - Hébert, Jacques
A1  - Kanani, Amin
A1  - Keith, Paul K.
A1  - Lacuesta, Gina
A1  - Yang, Bill
A1  - Aygören-Pürsün, Emel
A1  - Bernstein, Jonathan A.
A1  - Bork, Konrad
A1  - Caballero, Teresa
A1  - Cicardi, Marco
A1  - Craig, Timothy
A1  - Farkas, Henriette
A1  - Longhurst, Hilary
A1  - Zuraw, Bruce
A1  - Boysen, Henrik B.
A1  - Borici-Mazi, Rozita
A1  - Bowen, Tom
A1  - Dallas, Karen
A1  - Dean, John
A1  - Dean, John
A1  - Lang-Robertson, Kelly
A1  - Laramée, Benoît
A1  - Leith, Eric
A1  - Mace, Sean
A1  - McCusker, Christine
A1  - Moote, Bill
A1  - Poon, Man-Chiu
A1  - Ritchie, Bruce
A1  - Stark, Donald
A1  - Sussman, Gordon
A1  - Waserman, Susan
T1  - Canadian hereditary angioedema guideline
T2  - Allergy, asthma and clinical immunology
N2  - Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.
KW  - hereditary angioedema,
KW  - guideline
KW  - recommendations
KW  - acute attacks
KW  - short-term prophylaxis
KW  - long-term prophylaxis
KW  - self-administration
KW  - individualized therapy
KW  - quality of life
KW  - comprehensive care
KW  - GRADE
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/35391
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-353915
SN  - 1710-1492
SN  - 1710-1484
VL  - 10
IS  - 50
PB  - BioMed Central
CY  - London
ER  -